Barclays PLC Has $3.37 Million Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Barclays PLC raised its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 137.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 302,572 shares of the biopharmaceutical company’s stock after purchasing an additional 175,118 shares during the quarter. Barclays PLC owned approximately 0.23% of Dynavax Technologies worth $3,371,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares during the last quarter. US Bancorp DE increased its holdings in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the third quarter valued at approximately $45,000. Nisa Investment Advisors LLC raised its position in Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Centiva Capital LP bought a new position in Dynavax Technologies in the 3rd quarter valued at $119,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Up 0.9 %

Shares of NASDAQ DVAX opened at $12.83 on Tuesday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The stock has a market cap of $1.69 billion, a P/E ratio of 98.70 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The firm has a 50 day moving average price of $12.29 and a 200 day moving average price of $11.51.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.